Brain+

0.094

DKK

-0.42 %

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

4 following

-0.42%

-5.06%

+13.29%

-24.96%

-48.5%

-48.5%

-95.57%

-

-96.59%

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Market cap

19.94M DKK

Turnover

39.31K DKK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

ShowingAll content types

Press release12/10/2024, 7:45 AM

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Press release12/5/2024, 7:51 AM

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Press release11/21/2024, 2:30 PM

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/1/2024, 10:57 AM

Brain+ A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

Press release10/21/2024, 9:54 AM

Brain+ A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Press release10/11/2024, 7:04 AM

Brain+ A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions

Regulatory press release10/7/2024, 9:50 AM

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Press release10/2/2024, 8:32 AM

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Regulatory press release10/1/2024, 10:11 AM

Brain+ A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions

Press release10/1/2024, 7:23 AM

Brain+ A/S: Ayla - your CST Assistant has been registered in the UK as a certified Medical Device Software for dementia therapy

Press release9/25/2024, 8:43 AM

Brain+ A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK

Press release9/23/2024, 10:15 AM

Brain+ A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization

Regulatory press release9/20/2024, 6:43 AM

Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%

Regulatory press release9/17/2024, 8:46 AM

Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4

Press release9/13/2024, 8:33 AM

Brain+ A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Regulatory press release9/13/2024, 7:08 AM

Brain+ A/S announces the exercise price for its warrants of series TO 4

Press release9/5/2024, 7:30 AM

Brain+ A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment

Press release9/3/2024, 6:30 AM

Brain+ A/S: Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit

Press release8/30/2024, 10:35 AM

Brain+ A/S: Invitation to Investor Webinar on Tues 3 Sept 2024 at 16:00 CEST: H1 2024 report and new Chief Commercial Officer

Regulatory press release8/29/2024, 5:08 PM

Brain+ A/S: H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.